American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Whole genome sequencing comparison of acute myeloid leukemia at presentation and remission predicts patient outcome
    Meeting Abstract

    Moffitt, A. B.; Alexander, J.; Stepansky, A.; Famulare, C.; Lopez, C. A.; Hakim, N.; Wu, V.; Wang, Z.; Kolitz, J. E.; Chiorazzi, N.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • BCL6-mediated escape from negative selection enables RAS-driven B-cell transformation
    Meeting Abstract

    Chan, L. N.; Hurtz, C.; Robinson, M. E.; Leveille, E.; Geng, H.; Caeser, R.; Xu, L.; Kume, K.; Xiao, G.; Müschen, M.
    Blood (2022)

    Fulltext@MSK | Save
  • Correlative biomarkers for CART19 response in patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Batlevi, C. L.; Nos, G.; Kotlov, N.; Sorokina, M.; Okwali, M.; Bagaev, A.; Michaud, L.; Shah, G. L.; Shouval, R.; Tomas, A. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Erythroid and megakaryocytic differentiation program in JAK2-mutated acute myeloid leukemia with or without antecedent myeloproliferative neoplasm
    Meeting Abstract

    Liu, Y.; Sethi, S.; Koche, R.; Gao, Q.; Dilip, D.; Glass, J. L.; Galera, P. K.; Persaud, S.; Mishra, T.; Sun, X.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A Phase 1b dose escalation and expansion study of SNDX-5613, azacitidine (AZA) and venetoclax (VEN) in newly diagnosed, patients ≥ 60 years with untreated NPM1-mutated/ FLT3-wild type AML or KMT2A-rearranged acute myeloid leukemia (AML)
    Meeting Abstract

    Zeidner, J. F.; Foster, M. C.; Johnson, M.; Huang, Y.; Swords, R. T.; Stein, E.; Foran, J. M.; Baer, M. R.; Stock, W.; Madanat, Y. F.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Quantitative cytogenetic analysis with karyoParser allows for more precise identification of disease biology, clonal evolution, and etiology of relapse in acute myeloid leukemia
    Meeting Abstract

    Dilip, D.; Derkach, A.; Menghrajani, K.; Goldberg, A. D.; May, H.; Klimek, V. M.; Galera, P. K.; Xiao, W.; Zhang, Y.; Elemento, O.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A multi-center phase Ib trial of the histone deactylase inhibitor (HDACi) entinostat in combination with anti-pd1 antibody pembrolizumab in patients with refractory/relapsed myelodysplastic syndromes (RR-MDS) or oligoblastic acute myeloid leukemia (RR-AML) after hypomethylating agent (HMA) failure
    Meeting Abstract

    Bewersdorf, J. P.; Shallis, R. M.; Sharon, E.; Caldwell, A.; Wei, W.; Yacoub, A.; Madanat, Y. F.; Zeidner, J. F.; Altman, J. K.; Odenike, O.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Adolescent and young adults with ALL who complete therapy on DFCI Consortium ALL trials have excellent long-term overall survival
    Meeting Abstract

    Valtis, Y. K.; Flamand, Y.; Shimony, S.; Place, A. E.; Silverman, L. B.; Vrooman, L. M.; Brunner, A. M.; Sallan, S. E.; Wadleigh, M.; Stone, R. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Impact of allelic state on overall survival in TP53-mutant acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (HR-MDS)
    Meeting Abstract

    Bewersdorf, J. P.; Hasle, V.; Shallis, R. M.; Thompson, E. G.; de Menezes, D. L.; Rose, S.; Boss, I. W.; Halene, S.; Haferlach, T.; Fox, B.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Umbrella trial in myeloid malignancies: The myelomatch national clinical trials network precision medicine initiative
    Meeting Abstract

    Little, R. F.; Othus, M.; Assouline, S.; Ansher, S.; Atallah, E. L.; Lindsley, R. C.; Freidlin, B.; Gore, S. D.; Harris, L.; Hourigan, C. S.; more...
    Blood (2022)

    Fulltext@MSK | Save